Hugel Aesthetics launches direct sales force for Letybo in the U.S.

Hugel Aesthetics is launching a dedicated direct U.S. sales force and field-based medical affairs team for Letybo (letibotulinumtoxinA-wlbg), meaning your practice may soon see a shift in how this South Korean neurotoxin is supported and sold. Following its FDA approval in February 2024 and U.S. launch in March 2025, Hugel is adopting a hybrid commercial strategy. While Benev Company will continue servicing specific accounts, Hugel’s direct sales organization will focus on select strategic accounts throughout 2026. Letybo brings a heavy track record, having spent 10 years as the top-selling toxin in South Korea, where it competed against more than 15 other neuromodulators. Globally, the product has over 15 years of clinical experience and 44 million treatments across more than 70 countries. Hugel is also rolling out its K-TOX marketing campaign to build consumer demand around South Korean aesthetic innovation. For clinic owners, this dual-sales push means better direct clinical support and likely some aggressive pricing plays as Hugel attempts to carve out market share. It may be a highly leverageable moment to negotiate your back-bar pricing if you are looking to diversify your toxin offerings.

Source: Plastic Surgery Practice, https://www.plasticsurgerypractice.com/injectables/hugel-aesthetics-expands-us-support-for-letybo-with-direct-sales-force/